Dermata Therapeutics, Inc. — Director's Dealing 2021

Aug 17, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Dermata Therapeutics, Inc. (DRMA)
CIK: 0001853816
Period of Report: 2021-08-16

Reporting Person: PROEHL GERALD T (Director, President, CEO and Chairman, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-16	Common Stock	P	10000	$4.9631	Acquired	10000	Indirect
2021-08-17	Common Stock	C	17857	—	Acquired	17857	Indirect
2021-08-17	Common Stock	C	8928	—	Acquired	8928	Indirect
2021-08-17	Common Stock	C	35767	—	Acquired	35767	Indirect
2021-08-17	Common Stock	C	361147	—	Acquired	1278464	Indirect
2021-08-17	Common Stock	C	111951	—	Acquired	1390415	Indirect
2021-08-17	Common Stock	C	181585	—	Acquired	1572000	Indirect
2021-08-17	Common Stock	C	1247904	—	Acquired	2819904	Indirect
2021-08-17	Common Stock	C	85640	—	Acquired	2905544	Indirect
2021-08-17	Common Stock	P	142857	—	Acquired	152857	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-08-17	Series 1d Preferred Stock	$	C	120481	Disposed		Common Stock (17857)	Indirect
2021-08-17	Series 1d Preferred Stock	$	C	60240	Disposed		Common Stock (8928)	Indirect
2021-08-17	Series 1d Preferred Stock	$	C	241325	Disposed		Common Stock (35767)	Indirect
2021-08-17	Series 1d Preferred Stock	$	C	2436657	Disposed		Common Stock (361147)	Indirect
2021-08-17	Series 1a Preferred Stock	$	C	2295000	Disposed		Common Stock (111951)	Indirect
2021-08-17	Series 1b Preferred Stock	$	C	3722500	Disposed		Common Stock (181585)	Indirect
2021-08-17	Series 1c Preferred Stock	$	C	25582050	Disposed		Common Stock (1247904)	Indirect
2021-08-17	Series 1 Preferred Stock	$	C	1755622	Disposed		Common Stock (85640)	Indirect
2021-08-17	Series 1a Warrants	$	C	573750	Disposed	2026-03-14	Common Stock (27987)	Indirect
2021-08-17	Warrant to Purchase Common Stock	$20.50	C	27987	Acquired	2026-03-14	Common Stock (27987)	Indirect
2021-08-17	Warrant to Purchase Common Stock	$7.00	P	142857	Acquired	2026-08-17	Common Stock (142857)	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	39512	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.84 to $5.00 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

F2: The Series 1d Preferred Stock automatically converted into Common Stock of the Issuer upon consummation of the Issuer's initial public offering (the "IPO"). The Series 1d Preferred Stock was convertible at any time and had no expiration date.

F3: The Series 1a Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1a Preferred Stock was convertible at any time and had no expiration date.

F4: The Series 1b Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1b Preferred Stock was convertible at any time and had no expiration date.

F5: The Series 1c Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1c Preferred Stock was convertible at any time and had no expiration date.

F6: The Series 1 Preferred Stock converted into Common Stock of the Issuer upon consummation of the IPO. The Series 1 Preferred Stock was convertible at any time and had no expiration date.

F7: The Series 1a Preferred Warrants converted into warrants to purchase Common Stock in connection with the IPO.

F8: Reporting Person disclaims beneficial ownership of these securities except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F9: Reporting Person purchased 142,857 Units in the IPO at $7.00 per Unit Each Unit consists of one share of Common Stock and one warrant to purchase one share of Common Stock.